SG10201608234UA - Interrogatory cell-based assays and uses thereof - Google Patents

Interrogatory cell-based assays and uses thereof

Info

Publication number
SG10201608234UA
SG10201608234UA SG10201608234UA SG10201608234UA SG10201608234UA SG 10201608234U A SG10201608234U A SG 10201608234UA SG 10201608234U A SG10201608234U A SG 10201608234UA SG 10201608234U A SG10201608234U A SG 10201608234UA SG 10201608234U A SG10201608234U A SG 10201608234UA
Authority
SG
Singapore
Prior art keywords
based assays
interrogatory
cell
interrogatory cell
assays
Prior art date
Application number
SG10201608234UA
Inventor
Niven Rajin Narain
Rangaprasad Sarangarajan
Vivek K Vishnudas
Min Du
Tony Walshe
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of SG10201608234UA publication Critical patent/SG10201608234UA/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
SG10201608234UA 2012-04-02 2012-09-07 Interrogatory cell-based assays and uses thereof SG10201608234UA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261619326P 2012-04-02 2012-04-02
US201261620305P 2012-04-04 2012-04-04
US201261665631P 2012-06-28 2012-06-28
US201261668617P 2012-07-06 2012-07-06
US201261678596P 2012-08-01 2012-08-01
US201261678590P 2012-08-01 2012-08-01

Publications (1)

Publication Number Publication Date
SG10201608234UA true SG10201608234UA (en) 2016-11-29

Family

ID=49235335

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201608234UA SG10201608234UA (en) 2012-04-02 2012-09-07 Interrogatory cell-based assays and uses thereof
SG11201406201YA SG11201406201YA (en) 2012-04-02 2012-09-07 Interrogatory cell-based assays and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201406201YA SG11201406201YA (en) 2012-04-02 2012-09-07 Interrogatory cell-based assays and uses thereof

Country Status (14)

Country Link
US (2) US10061887B2 (en)
EP (1) EP2834366A4 (en)
JP (3) JP6189926B2 (en)
KR (2) KR20200105524A (en)
CN (3) CN104520435A (en)
AU (2) AU2012376214B2 (en)
BR (1) BR112014024537A2 (en)
CA (1) CA2869296A1 (en)
EA (1) EA038600B1 (en)
HK (1) HK1209161A1 (en)
IL (1) IL234920B (en)
MX (1) MX357392B (en)
SG (2) SG10201608234UA (en)
WO (1) WO2013151577A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501859B (en) * 2011-03-02 2017-08-25 博格有限责任公司 Probing analysis and its application based on cell
EP2668945A1 (en) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotype and phenotype-based medicinal formulations
US9449284B2 (en) * 2012-10-04 2016-09-20 Nec Corporation Methods and systems for dependency network analysis using a multitask learning graphical lasso objective function
CN103558354B (en) * 2013-11-15 2015-07-15 南京大学 Water toxicity analysis method based on biologic omics integrated technology
WO2015196080A1 (en) * 2014-06-20 2015-12-23 Connecticut Children's Medical Center Automated cell culture system and corresponding methods
US10482385B2 (en) 2014-09-11 2019-11-19 Berg Llc Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data
CN105624275B (en) * 2014-11-06 2020-03-27 上海市东方医院 Application of EIF4G1 in diagnosis and treatment of squamous cell carcinoma
JP6270221B2 (en) 2015-02-13 2018-01-31 国立研究開発法人産業技術総合研究所 Biomarker search method, biomarker search device, and program
KR101786859B1 (en) * 2015-04-30 2017-10-17 서울대학교산학협력단 Method for monitoring clinical and pathological alzheimer's disease using amyloid beta concentration in plasma
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
CA2987383C (en) * 2015-05-28 2023-10-24 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Assays to identify genetic elements affecting phenotype
CN106250717B (en) * 2015-06-04 2019-03-12 徐勇 The miRNA of acute myeloid leukaemia and the system of transcription factor and its construction method and application
US20160363567A1 (en) * 2015-06-15 2016-12-15 Lunatech, Llc Vapor Device For Stressing And Analyzing Compounds
JP6325177B2 (en) * 2015-10-14 2018-05-16 公立大学法人横浜市立大学 Blood biomarkers for determining the effects of renal cancer drug therapy
WO2017214572A1 (en) * 2016-06-10 2017-12-14 The Regents Of The University Of California Image-based cell sorting systems and methods
EP3538095A4 (en) 2016-11-14 2020-06-17 Berg LLC Methods for treating parkinson's disease
CN106834105A (en) * 2017-02-21 2017-06-13 齐齐哈尔医学院 A kind of apparatus and method for epigenetic analysis
US11636917B2 (en) * 2017-06-28 2023-04-25 The Regents Of The University Of California Simulating the metabolic pathway dynamics of an organism
CN107475346B (en) * 2017-08-11 2021-08-06 北京汉典制药有限公司 Method for in vitro screening of diabetic nephropathy medicine
JP6902977B2 (en) * 2017-09-22 2021-07-14 新日本無線株式会社 How to detect a failure in the startup circuit
EP3697925A4 (en) * 2017-10-18 2021-06-23 Venn Biosciences Corporation Identification and use of biological parameters for diagnosis and treatment monitoring
JP2021073432A (en) * 2018-03-02 2021-05-13 国立研究開発法人医薬基盤・健康・栄養研究所 Screening method of activated kinase being therapeutic target
JP7176381B2 (en) * 2018-12-03 2022-11-22 富士通株式会社 Structure search method for cyclic molecule, structure search device, and program
CN109536473A (en) * 2018-12-19 2019-03-29 华中科技大学鄂州工业技术研究院 The method for integrating key protein matter kinases in multiple groups data-speculative cells transdifferentiate
JP2022523564A (en) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド Data compression and communication using machine learning
WO2020264379A1 (en) * 2019-06-26 2020-12-30 Berg Llc Markers for the diagnosis of prostate cancer
JP2023517076A (en) * 2020-03-10 2023-04-21 エイアイ：オン イノベーションズ、インコーポレイテッド Systems and methods for mammalian transfer learning
US11227690B1 (en) * 2020-09-14 2022-01-18 Opendna Ltd. Machine learning prediction of therapy response
CN113035298B (en) * 2021-04-02 2023-06-20 南京信息工程大学 Drug clinical trial design method for recursively generating large-order line limiting coverage array
CN113138249B (en) * 2021-04-12 2021-11-23 北京蛋白质组研究中心 Micro-sample metabolome, proteome and phosphoproteome multi-group chemical analysis method based on micropore array chip
EP4338163A1 (en) * 2021-05-13 2024-03-20 Scipher Medicine Corporation Assessing responsiveness to therapy
CN113943720A (en) * 2021-11-03 2022-01-18 江苏省农业科学院 Apolygus lucorum GRK gene, dsRNA thereof, synthetic method and application thereof
WO2023230268A1 (en) * 2022-05-27 2023-11-30 Memorial Sloan-Kettering Cancer Center Systems and methods for metabolite imputation
CN117417914A (en) * 2022-07-18 2024-01-19 华东师范大学 Marker for preventing and protecting cerebral ischemia diseases and application of aspirin derivative in preventing and protecting cerebral ischemia diseases
WO2024081740A1 (en) * 2022-10-13 2024-04-18 Somalogic Operating Co., Inc. Systems and methods for validation of proteomic models

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
DE768377T1 (en) 1988-09-02 1998-01-02 Dyax Corp Production and selection of recombinant proteins with different binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (en) 1990-07-10 2000-04-17 Cambridge Antibody Tech Process for producing specific binding pair elements
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
DE69233697T2 (en) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Process for the development of binding microproteins
DE69233750D1 (en) 1991-04-10 2009-01-02 Scripps Research Inst Libraries of heterodimeric receptors using phagemids
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
DE69233331T3 (en) 1991-11-22 2007-08-30 Affymetrix, Inc., Santa Clara Combinatorial Polymersynthesis Strategies
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
EP1262564A3 (en) 1993-01-07 2004-03-31 Sequenom, Inc. Dna sequencing by mass spectrometry
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
CA2158642A1 (en) 1993-03-19 1994-09-29 Hubert Koster Dna sequencing by mass spectrometry via exonuclease degradation
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc Nucleic acid analysis techniques
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
AU1287799A (en) 1997-10-31 1999-05-24 Affymetrix, Inc. Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6763307B2 (en) * 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
JP2004533223A (en) * 2001-03-13 2004-11-04 アッシュニ ナチュラシューティカルズ，インコーポレイティド Methods for associating genomic and proteomic pathways involved in physiological or pathophysiological processes
US8000949B2 (en) * 2001-06-18 2011-08-16 Genego, Inc. Methods for identification of novel protein drug targets and biomarkers utilizing functional networks
US7393656B2 (en) * 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
ATE398808T1 (en) 2002-08-29 2008-07-15 Gene Network Sciences Inc SYSTEMS AND METHODS FOR INFERENCE ON BIOLOGICAL NETWORKS
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
JP4288345B2 (en) * 2003-06-19 2009-07-01 独立行政法人産業技術総合研究所 New epilepsy model animal
EP1512970A1 (en) * 2003-09-05 2005-03-09 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for determining the impact of a multicomponent mixture on the biological profile of a disease
WO2005035780A1 (en) * 2003-10-14 2005-04-21 Cellfree Sciences Co.,Ltd. Novel method of screening indicator substance
US8185367B2 (en) 2004-04-30 2012-05-22 Merck Sharp & Dohme Corp. Systems and methods for reconstructing gene networks in segregating populations
EP1607898A3 (en) * 2004-05-18 2006-03-29 Neal E. Solomon A bioinformatics system for functional proteomics modelling
US20100316629A1 (en) 2004-09-01 2010-12-16 Shaughnessy Jr John D Use of gene expression profiling to predict survival in cancer patient
WO2006054991A1 (en) * 2004-11-17 2006-05-26 Immunivest Corporation Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection
EP1842147A2 (en) * 2005-01-24 2007-10-10 The Board of Trustees of The Leland Stanford Junior University Method for modeling cell signaling systems by means of bayesian networks
WO2006129401A1 (en) * 2005-05-31 2006-12-07 Jcl Bioassay Corporation Screening method for specific protein in proteome comprehensive analysis
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
EP1928909A1 (en) 2005-09-30 2008-06-11 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
WO2008060620A2 (en) * 2006-11-15 2008-05-22 Gene Network Sciences, Inc. Systems and methods for modeling and analyzing networks
JP2009050171A (en) * 2007-08-23 2009-03-12 Toyobo Co Ltd Method for detecting phosphorylation on substrate by surface plasmon resonance
AU2008333811B2 (en) 2007-12-04 2014-05-01 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
EA022884B1 (en) * 2008-08-15 2016-03-31 Мерримак Фармасьютикалз, Инк. METHOD FOR TREATING NEOPLASTIC TUMOR USING ANTI-ErbB3 ANTIBODY
EP3467123A3 (en) * 2008-11-17 2019-07-31 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
KR20120034649A (en) * 2009-05-11 2012-04-12 버그 바이오시스템즈, 엘엘씨 Methods for treatment of disease using an epimetabolic shifter (coenzyme q10)
EP2600154A4 (en) 2010-03-31 2014-06-11 Univ Kumamoto Nat Univ Corp Method for generating data set for integrated proteomics, integrated proteomics method using data set for integrated proteomics that is generated by the generation method, and method for identifying causative substance using same
CN103501859B (en) 2011-03-02 2017-08-25 博格有限责任公司 Probing analysis and its application based on cell

Also Published As

Publication number Publication date
WO2013151577A9 (en) 2014-11-20
JP2018033448A (en) 2018-03-08
KR102149070B1 (en) 2020-10-15
KR20200105524A (en) 2020-09-07
JP6189926B2 (en) 2017-08-30
IL234920A0 (en) 2014-12-31
AU2012376214A1 (en) 2014-10-30
AU2019200670A1 (en) 2019-02-21
NZ700647A (en) 2016-08-26
NZ718138A (en) 2017-11-24
JP2015519876A (en) 2015-07-16
AU2012376214B2 (en) 2019-02-14
EA201491833A1 (en) 2015-01-30
AU2019200670B2 (en) 2021-09-23
WO2013151577A8 (en) 2014-12-31
MX357392B (en) 2018-07-06
JP2021003121A (en) 2021-01-14
CN110456035A (en) 2019-11-15
HK1209161A1 (en) 2016-03-24
EP2834366A1 (en) 2015-02-11
JP6767320B2 (en) 2020-10-14
CN104520435A (en) 2015-04-15
US10061887B2 (en) 2018-08-28
CN108048521A (en) 2018-05-18
SG11201406201YA (en) 2014-10-30
KR20140142357A (en) 2014-12-11
CN108048521B (en) 2022-05-27
IL234920B (en) 2019-12-31
CA2869296A1 (en) 2013-10-10
US20190279736A1 (en) 2019-09-12
MX2014011797A (en) 2014-12-10
EA038600B1 (en) 2021-09-21
US20130259847A1 (en) 2013-10-03
WO2013151577A1 (en) 2013-10-10
EP2834366A4 (en) 2016-04-27
BR112014024537A2 (en) 2017-08-08

Similar Documents

Publication Publication Date Title
IL257824A (en) Interrogatory cell-based assays and uses thereof
HK1209161A1 (en) Interrogatory cell-based assays and uses thereof
HK1251033A1 (en) Whole cell assays and methods
HK1207092A1 (en) Anti-hla-b27 antibodies and uses thereof -hla-b27
HRP20190358T1 (en) Anti-asic1 antibodies and uses thereof
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
HK1205523A1 (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof ---1(big-et-1)
HK1212390A1 (en) Assay methods and systems
EP2819749A4 (en) Autism-associated biomarkers and uses thereof
GB201220662D0 (en) Assays
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
GB201211158D0 (en) Biomarkers and uses thereof
GB201212550D0 (en) B cell assay
GB201218438D0 (en) Biomarkers and uses thereof
GB201208372D0 (en) Antibodies and uses thereof